Clinical and economic impact of treated CMV infection in adult CMV‐seropositive patients after allogeneic hematopoietic cell transplantation-Reference-Cited by-同舟云学术

Clinical and economic impact of treated CMV infection in adult CMV‐seropositive patients after allogeneic hematopoietic cell transplantation

Published:2020-06-29 Issue:12 Volume:92 Page:3665-3673
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:Journal of Medical Virology

Author:

Peffault De Latour Régis¹^ORCID,Chevallier Patrice²,Blaise Didier³,Alami Sarah⁴,Lévy‐Bachelot Laurie⁴,Allavoine Thierry⁴,Tadmouri Abir⁵,Blomkvist Josefin⁵,Duhamel Alain⁶,Srour Micha⁷,Beauvais David⁷⁸,Yakoub‐Agha Ibrahim⁹

Affiliation:

1. Hematology‐Transplantation Paris Diderot University, Saint‐Louis Hospital Paris France

2. Clinical Hematology Nantes University Hospital Nantes France

3. Institut Paoli Calmettes, Department of Hematology Centre de Recherche en Cancérologie de Marseille (CRCM) Marseille France

4. MSD France Courbevoie France

5. ClinSearch Malakoff France

6. Université de Lille, CHU Lille, EA 2694 ‐ Santé publique: épidémiologie et qualité des soins Lille France

7. Hematology Department Claude Huriez Hospital Lille France

8. Lille University Hospital Lille France

9. CHU de Lille, LIRIC, INSERM U995, Université de Lille Lille France

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.25895

Reference34 articles.

1. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients

2. The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT

3. Cytomegalovirus: pathogen, paradigm, and puzzle

4. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)

5. How we treat cytomegalovirus in hematopoietic cell transplant recipients

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytomegalovirus inhibitors of programmed cell death restrict antigen cross-presentation in the priming of antiviral CD8 T cells;PLOS Pathogens;2024-08-15

2. Cytomegalovirus inhibitors of programmed cell death prevent a contribution of antigen cross-presentation to the priming of antiviral CD8 T cells;2024-04-13

3. Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighting the Role of Advanced Practice Providers (Nurse Practitioners and Physician Assistants);Annals of Transplantation;2024-03-15

4. Treatment for First Cytomegalovirus Infection Post–Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir;Clinical Infectious Diseases;2023-11-30

5. Cytomegalovirus reactivation under pre-emptive therapy following allogeneic hematopoietic stem cell transplant: Pattern, survival, and risk factors in the Republic of Korea;PLOS ONE;2023-09-13